Search results for: Innovation Policy Prize
Filter search results
The World Needs Better Drugs for TB. The Center for Global Development and OHE Have a Proposal and We Need your Feedback
5 March 2019
Innovation is a critical tool in the global fight against tuberculosis (TB), an infectious disease that primarily affects the poor and vulnerable and ranks among the top 10 causes of…
Biosimilars and Data Exclusivity
8 June 2010
Data exclusivity is critical to ensuring that biosimilars achieve an appropriate balance between increasing market competition and encouraging innovation. The history of ‘traditional generics’ is a poor guide; biosimilars possess…
Meeting the Challenges of Drug Development in 2022: Summary of OHE’s 50th Anniversary Conference
11 October 2012
…New approaches to R&D that spread risks, and share benefits, are important to incentives for innovation and potentially involve a wide range of public and private parties Encouraging innovation includes…
OHE’s submission to Belgium’s Committee on Health and Equal Opportunities argues value-based pricing delivers a ‘triple-win’
18 December 2024
…innovation. • Access to the most valuable innovations to be prioritised. • Price signals to be aligned with patient and societal priorities. • The level of investment in pharmaceuticals, and…
OHE at ISPOR Latin America: Policy Options for Formulary Development in Middle-income Countries
20 October 2015
This post summarises OHE’s activities at this year’s ISPOR Latin America conference in Santiago, September 2015. Topics include policy options for formulary development in middle-income countries, and role of HTA…
Cornerstones of ‘Fair’ Drug Coverage
30 September 2020
…and clinical societies joined ICER’s Policy Leadership Forum – senior policy leaders from 25 payers and life science companies – in December 2019 to discuss a preliminary draft of this…
New Drugs to Tackle Antimicrobial Resistance: EU Policy Options
1 October 2010
…policy discussions. The paper reviews AMR’s implications for the burden of disease, the causes of AMR, the current state of the antibiotic development pipeline and the reasons antibiotic R&D has…
Trade and Price Differentials for Pharmaceuticals: Policy Options
1 May 1997
…presence of joint costs. Section 4 identifies the winners and losers from parallel trade. Sections 5 and 6 discuss policy options to minimize the adverse impact of parallel trade and…
The Dynamics of Drug Shortages
9 January 2024
…recommendations for policy makers. Key takeaways Drug shortages occur globally, across a range of therapeutic areas, but appear to be mostly centered around the generic and biosimilar markets. The causes…